Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BCMA-CD38 dual-target autologous CAR-T cells for relapsed or refractory multiple myeloma
ChiCTR2000041200Phase 2Recruiting
- Sponsor
- Shenzhen Nanshan People's Hospital
- Start
- Dec 2020
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of BCMA-CD38 dual-target autologous CAR-T cells in multiple myeloma (MM), sponsored by Shenzhen Nanshan People's Hospital. Primary endpoints: Complete response rate, CAR-T cells and 1 more. Started Dec 2020; status: recruiting.
02
Drugs
BCMA-CD38 dual-target autologous CAR-T cells
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on ChiCTR2000041200.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2000041200.